We are developing “single enzyme activity-based liquid biopsy”
for early detection of diseases and drug development support.
We are developing high-precision liquid-based diagnostic technology using "single enzyme activity-based protein profiling (SEAP),"
to evaluate the activity of enzymes in the blood molecule at single protein level.
Our business focuses on 2 main areas: early disease diagnosis and support for drug development.
For example, by utilizing our "single enzyme activity-based protein profiling (SEAP)" technology, pancreatic cancer may be detected in its early stage.
We will contribute to future growth of healthcare
by applying fluorescent enzyme substrates and microdevices.